Institute of Toxicology, College of Preventive Medicine, Third Military Medical University, Chongqing 400038, PR China.
Department of Neurology, Southwest Hospital, Third Military Medical University, Chongqing 400038, PR China.
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt A):1086-1103. doi: 10.1016/j.bbadis.2018.01.013. Epub 2018 Jan 17.
Parkinson's disease (PD) is the second most common age-related neurodegenerative disease. Mitochondrial dysfunction has been the focus of the pathogenesis of PD. The mitochondrial ATP-sensitive potassium channel (mitoKATP) plays a significant role in mitochondrial physiology and has been extensively shown to protect against ischemic and brain reperfusion injury. However, there have long been controversies regarding its role in Parkinson's disease. We investigated the role of mitoKATP channels in rotenone-induced PD model in vivo and vitro and the interactions of mitoKATP channels, mitochondrial dynamics and PD. The results indicated that the use of diazoxide to activate mitoKATP channels resulted in the aggravation of rotenone-induced dopamine neurodegeneration in PC12 cells and SD rats. In contrast, the use of 5-hydroxydecanoate (5-HD) to inhibit mitoKATP channels improved rotenone-induced dopamine neurodegeneration, which was not consistent with mitoKATP channels in ischemic and brain reperfusion injury. Further analysis determined that the mitoKATP channel was involved in PD mainly via the regulation of mitochondrial biogenesis and fission/fusion. And the pore subunits of Kir6.1, the major component of mitoKATP channels, was the key contributor in its interaction with mitochondrial dynamics in rotenone-induced dopamine neurodegeneration. Therefore, it can be concluded that mitoKATP channels regulate mitochondrial dynamics to participate in rotenone-induced PD mainly attributes to the pore subunits of Kir6.1. And additionally, though mitoKATP channels may represent a direction of one potential target for neuroprotection, it should be noted that the effects are different in the activation or inhibition of mitoKATP channels in different models.
帕金森病(PD)是第二常见的与年龄相关的神经退行性疾病。线粒体功能障碍一直是 PD 发病机制的焦点。线粒体 ATP 敏感性钾通道(mitoKATP)在线粒体生理学中起着重要作用,并已广泛证明可预防缺血和脑再灌注损伤。然而,其在帕金森病中的作用一直存在争议。我们研究了 mitoKATP 通道在体内和体外鱼藤酮诱导的 PD 模型中的作用,以及 mitoKATP 通道、线粒体动力学和 PD 之间的相互作用。结果表明,使用二氮嗪激活 mitoKATP 通道会导致鱼藤酮诱导的 PC12 细胞和 SD 大鼠多巴胺神经变性加重。相比之下,使用 5-羟基癸酸(5-HD)抑制 mitoKATP 通道可改善鱼藤酮诱导的多巴胺神经变性,这与缺血和脑再灌注损伤中的 mitoKATP 通道不一致。进一步分析确定,mitoKATP 通道主要通过调节线粒体生物发生和裂变/融合参与 PD。并且,Kir6.1 的孔亚基,mitoKATP 通道的主要组成部分,是其在鱼藤酮诱导的多巴胺神经变性中与线粒体动力学相互作用的关键贡献者。因此,可以得出结论,mitoKATP 通道通过调节线粒体动力学来参与鱼藤酮诱导的 PD,主要归因于 Kir6.1 的孔亚基。此外,尽管 mitoKATP 通道可能代表神经保护的一个潜在靶点方向,但应注意,在不同模型中激活或抑制 mitoKATP 通道的效果不同。